Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
aTyr Pharma Inc Market Cap
The aTyr Pharma Inc (LIFE) share price is expected to increase by 1060.38% over the next year. This is based on calculating the average 12-month share price estimate provided by 5 stock analysts who have covered LIFE. Price targets range from $16 at the low end to $35 at the high end. The current analyst consensus for LIFE is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
aTyr Pharma Inc has a total of 5 Wall St Analyst ratings. There are 1 buy ratings, 4 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that aTyr Pharma Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of LIFE.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | May 14, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | May 3, 2024 |
HC Wainwright& Co. | Buy | Reiterates | May 3, 2024 | |
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | Mar 15, 2024 |
| Gregory Renza RBC Capital | Outperform | $16 | Maintains | Mar 15, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | Feb 21, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | Sep 21, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | Sep 14, 2023 |
HC Wainwright & Co. | Buy | Reiterates | Aug 10, 2023 | |
Piper Sandler | Overweight | Maintains | Jul 21, 2023 | |
| Hartaj Singh Oppenheimer | Perform | Downgrade | Jul 5, 2023 | |
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | May 23, 2023 |
| Gregory Renza RBC Capital | Outperform | $19 | Reiterates | May 10, 2023 |
| Edward Tenthoff Piper Sandler | Overweight | $13 | Maintains | Apr 11, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | Mar 10, 2023 |
| Gregory Renza RBC Capital | Outperform | $19 | Reiterates | Mar 10, 2023 |
| Kumaraguru Raja Roth MKM | Buy | $9 | Reinstates | Mar 6, 2023 |
| Gregory Renza RBC Capital | Outperform | $19 | Maintains | Mar 2, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $35 | Reiterates | Feb 7, 2023 |
| Edward Tenthoff Piper Sandler | Overweight | $14 | Maintains | Aug 16, 2022 |
When did it IPO
2015
Staff Count
56
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Sanjay S. Shukla M.D., M.S.
Market Cap
$131.1M
In 2023, LIFE generated $353,000 in revenue, which was a decrease of -96.60% from the previous year. This can be seen as a signal that LIFE's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 05 Jun 2024
Sentiment - NEUTRAL
Source - InvestorPlace
Summary - Investors can potentially earn significant returns in the stock market with modest capital and a mix of risk and luck. The article discusses seven $2 stocks that could increase tenfold by 2025.
Why It Matters - The focus on low-cost stocks with high growth potential highlights opportunities for significant returns, appealing to investors seeking affordable entry points in the market.
Mon, 03 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - aTyr Pharma, Inc. will change its Nasdaq ticker symbol from "LIFE" to "ATYR," effective June 5, 2024, marking a rebranding for the clinical stage biotech company.
Why It Matters - Ticker symbol changes can impact liquidity and investor perception. aTyr Pharma's rebranding may attract new interest and potentially affect stock performance.
Fri, 24 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - aTyr Pharma granted nonstatutory stock options for 9,400 shares at $1.86 each to new employees, aligning with Nasdaq rules and the company's 2022 Inducement Plan.
Why It Matters - The granting of stock options signals management's confidence in the company's future and may attract talent, potentially driving innovation and growth, which can impact stock performance.
Tue, 14 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The DSMB recommends continuing the study of efzofitimod without modifications, indicating a favorable safety profile for the treatment.
Why It Matters - The DSMB's endorsement of efzofitimod's safety boosts confidence in its potential, likely enhancing investor sentiment and encouraging investment in the related biotech company.
Wed, 15 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - aTyr Pharma will present data on its lead candidate efzofitimod at the ATS 2024 Conference, highlighting its anti-inflammatory effects in pulmonary sarcoidosis.
Why It Matters - Data presentation at ATS 2024 could enhance aTyr Pharma's credibility and attract investor interest, potentially impacting stock performance based on efzofitimod's efficacy in treating pulmonary sarcoidosis.
Thu, 02 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Enrollment for the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis is expected to complete by Q2 2024. The company reported $87.7 million in cash and equivalents as of Q1 2024.
Why It Matters - Completion of enrollment in the EFZO-FIT™ study could lead to pivotal data impacting efzofitimod’s market potential. Strong cash reserves suggest financial stability for ongoing research.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
